Related Experiment Video
Updated: May 21, 2026
Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins
Published on: July 8, 2025
Quantifying the structural requirements for designing newer FLT3 inhibitors
Rajiv Kumar Kar1, Priyanka Suryadevara, Rajesh Roushan
1Biomedical Informatics Centre, Rajendra Memorial Research Institute of Medical Sciences, Agamkuan, Patna-800007, Bihar, India.
Abstract:
RTKs - Receptor Tyrosine Kinases are the key regulators for cellular function and any abnormalities in the signaling of such leads to cancer. Mutations that result in the constitutive activation of this receptor result in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia. Pharmacophore mapping, a well-established method is used to build up 3D QSAR model from two classes of compounds viz. 2-acylaminothiophene-3-carboxamide derivatives and 4-amino-6-piperazin-1yl-pyrimidine-5-carbaldehyde oxime derivatives, which helps us to quantify the crucial structural requirements for designing newer potent inhibitors for FLT3. The derived model AADHR.939 (Pearson- R = 0.8912, q(2) = 0.7471 and non-cross-validated r(2) = 0.9154) shows that the ring feature is quite crucial for the FLT3 inhibitory activity. Moreover the model is showing 94% predicted activity, which makes an understanding that the model is capable of finding newer potent molecules from any database.
Insights
Receptor Tyrosine Kinases (RTKs) are crucial for cell function; their dysregulation causes leukemia. This study developed a 3D QSAR model to identify key structural features for potent FLT3 inhibitors, aiding new drug design.
Area of Science:
- Medicinal Chemistry
- Computational Biology
- Oncology
Background:
- Receptor Tyrosine Kinases (RTKs) are vital regulators of cellular processes.
- Aberrant RTK signaling, particularly FLT3 mutations, is implicated in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia.
- Targeting RTKs offers a therapeutic strategy for hematological malignancies.
Purpose of the Study:
- To develop a 3D Quantitative Structure-Activity Relationship (QSAR) model for identifying potent FLT3 inhibitors.
- To elucidate crucial structural requirements for effective FLT3 inhibition.
- To create a predictive model for discovering novel FLT3-targeting drug candidates.
Main Methods:
- Pharmacophore mapping was employed to build the 3D QSAR model.
- Two distinct chemical classes were analyzed: 2-acylaminothiophene-3-carboxamide derivatives and 4-amino-6-piperazin-1yl-pyrimidine-5-carbaldehyde oxime derivatives.
- Statistical validation metrics (Pearson's R, q(2), non-cross-validated r(2)) were used to assess model performance.
Main Results:
- A robust QSAR model, AADHR.939, was successfully derived with high statistical significance (R=0.8912, q(2)=0.7471, r(2)=0.9154).
- The model highlights the critical role of specific ring features in conferring FLT3 inhibitory activity.
- The developed model demonstrated a high predictive accuracy of 94%.
Conclusions:
- The 3D QSAR model provides valuable insights into the structural determinants of FLT3 inhibition.
- This predictive model can effectively screen databases for novel, potent FLT3 inhibitors.
- The findings facilitate the rational design of next-generation therapeutics for FLT3-driven leukemias.
Related Concept Videos
01:28Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase